High MAL2 expression predicts shorter survival in women with triple-negative breast cancer.
Clin Transl Oncol
; 26(10): 2549-2558, 2024 Oct.
Article
in En
| MEDLINE
| ID: mdl-38769215
ABSTRACT
INTRODUCTION:
Due to its lack of conventional surface receptors, triple-negative breast cancer (TNBC) is inherently resistant to most targeted therapies. MAL2 overexpression prompts endocytosis, conferring resistance to novel therapeutics. This study explores the role of MAL2 and PD-L1 in TNBC patients' prognosis.METHODS:
We performed immunohistochemical analysis on 111 TNBC samples collected from 76 patients and evaluated the expression of MAL2 and PD-1. We expanded the study by including The Cancer Genome Atlas (TCGA) cohort.RESULTS:
MAL2 expression did not correlate with stage, grade, tumor size, lymph node invasion, metastasis, and PD-1 expression. Patients with high MAL2 had significantly lower 5-year survival rates (71.33% vs. 89.59%, p = 0.0224). In the tissue microarray cohort (TMA), node invasions, size, recurrence, and low MAL2 (HR 0.29 [CI 95% 0.087-0.95]; p < 0.05) predicted longer patients' survival. In the TCGA cohort, patients with low MAL2 had significantly longer overall survival and disease-specific survival than patients with high MAL2. Older age and high MAL2 expression were the only independent predictors of shorter patient survival in the BRCA TCGA cohort.CONCLUSION:
High MAL2 predicts unfavorable prognosis in triple-negative breast cancer, and its expression is independent of PD-1 levels and clinicopathological features of TNBC.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Myelin and Lymphocyte-Associated Proteolipid Proteins
/
Triple Negative Breast Neoplasms
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Clin Transl Oncol
Year:
2024
Document type:
Article
Affiliation country:
Poland
Country of publication:
Italy